Hepatitis B Patients Encouraged To Sue Japan After Hepatitis C Settlement
This article was originally published in PharmAsia News
The successful negotiation to get the Japanese government to compensate hepatitis C patients infected by contaminated blood has encouraged hepatitis B patients to sue. More than 500 patients are expected to join in suits that begin reaching courts in March, seeking government financial and medical assistance. The suits contend the patients were infected through contaminated vaccine syringes, for which at least one state has been found responsible for five cases by the Supreme Court. (Click here for more
You may also be interested in...
The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.
Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9BN By 2024 Amid Rising Chronic Disease
The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.